The USFDA conducted a follow-up current Good Manufacturing Practices (cGMP) inspection at Cipla’s Pithampur facility between August 17 and August 25, 2026. At the conclusion of the inspection, the company received seven observations in Form 483.
Cipla said it will work closely with the USFDA and address the observations comprehensively within the stipulated timeframe.
Citi sees limited near-term earnings impact
Despite the latest observations, brokerage firm Citi maintained its ‘Buy’ rating on Cipla with a target price of ₹1,700, implying an upside of around 20.1% from Tuesday’s closing price of ₹1,415.Citi expects the latest USFDA observations to have no impact on near- to medium-term earnings, as key pipeline approvals are linked to the company’s Goa and US facilities.
While the details of the seven observations are yet to be disclosed, Citi said even a further delay in regulatory resolution is unlikely to affect its earnings estimates, given that the Pithampur facility is already under a Warning Letter.
However, a resolution of the regulatory issues at Pithampur would be a significant positive over the longer term, according to Citi. It would allow Cipla to manage supplies of key respiratory products, including generic Symbicort and generic Ventolin, more efficiently.
Pithampur inspection follows earlier regulatory disclosures
The latest inspection follows Cipla’s earlier disclosures dated February 18, August 5 and November 18, 2023, regarding regulatory action concerning the facility.
The company did not provide details of the individual observations in its exchange filing.
A Form 483 is issued by USFDA inspectors at the conclusion of an inspection when they identify observations that may indicate areas of non-compliance. The issuance of the form does not represent a final determination by the regulator.
Brokerage consensus and stock movement
According to Bloomberg analyst data, 26 of the 41 analysts covering Cipla recommend ‘Buy’, while nine have a ‘Hold’ rating and six recommend ‘Sell’.
Cipla shares opened lower on Wednesday and were trading at ₹1,418.50 as of 9.25 am, down 0.45%. The stock has fallen nearly 6% so far this year and more than 10% over the last 12 months.
Also read: GMR Airports Share Price: Jefferies sees 36% upside, says Hyderabad tariff outlook remains intact
